Boryung
↗Seoul, South Korea
Boryung Corporation (formerly Boryung Pharmaceutical) is a leading South Korean healthcare company specializing in the development, manufacture, and distribution of specialty and generic drugs. The company is best known for its flagship hypertension drug, Kanarb (fimasartan), which was the first domestically developed novel drug in Korea to achieve significant commercial success. Boryung operates with a strong focus on chronic diseases, including cardiovascular, oncology, diabetes, and CNS disorders.
In recent years, Boryung has pivoted toward an 'LBA' (Legacy Brand Acquisition) strategy, acquiring established global brands like Gemzar, Zyprexa, and Alimta to solidify its market position. Additionally, the company has made headlines for its strategic expansion into 'Space Health' through its 'Humans In Space' (HIS) program, investing in global space infrastructure firms like Axiom Space and Intuitive Machines to explore healthcare solutions for long-term space habitation.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology and Cardiovascular Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$745M
Founded:1963
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Public Shareholders, Boryung Holdings
STOCK
Exchange:KRX
Ticker:003850
Market Cap:$533M
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Kanarb)
Modalities:Small molecule, Biosimilar, Combination therapy
Active Trials:161
Trial Phases:Phase 1: 12 | Phase 2: 5 | Phase 3: 8 | Phase 4: 20
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Boryung Holdings
Subsidiaries:Boryung Biopharma, Boryung Consumer Healthcare, BRAX Space (Joint Venture)
Key Partnerships:Axiom Space (Space health infrastructure), Sanofi (Acquisition of Taxotere business), HK inno.N (Co-marketing K-CAB), Zuellig Pharma (CDMO for Alimta in SE Asia)
COMPETITION
Position:Leader
Competitors:Hanmi Pharmaceutical, Yuhan Corporation, Daewoong Pharmaceutical, GC Biopharma
LEADERSHIP
Key Executives:
Jung-Gyun (Jay) Kim - Chairman & CEO
Doo-Hyun (Daniel) Jang - CEO
Scientific Founders:Seung-ho Kim
Board Members:Jung-Gyun Kim, Jae-Hyun Ahn, Jung-Kwon Yoo
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Boryung. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.